It’s a new calendar year – yet the tired drug pricing control policies of 2021 continue to float around Capitol Hill. Proponents of price controls justify their actions by claiming drug prices are “skyrocketing” and hurting Americans. That’s not surprising; For years drug prices have been a…

We are on the precipice of a looming crisis. Antimicrobial resistance (AMR) is the evolution of deadly pathogens like bacteria and fungi to resist all current antimicrobial medicines. In this episode, we talk about how the dwindling supply of new antibiotics is fueling this silent pandemic, and why…

They are not the household names, but the medications they are researching and developing could be the lifeline patients are waiting for. Today we explore how drug price controls—now making their way through Congress—could have unintended consequences for the small biotechs that are the engine of…

It’s no secret that the United States spends more on health care than other nations. In response to this problem, policymakers in Washington – including President Trump and Speaker Nancy Pelosi – want to impose foreign price setting schemes on prescription medicines that America’s patients rely on…

In case you missed it, the Trump administration is moving forward with a plan to import into the United States dangerous government price setting for innovative cures and treatments. In a nutshell, the move will harm the scientists and researchers working around the clock to eradicate Covid-19,…

The 22nd annual BIO CEO & Investor Forum kicked off today with a Welcome and Update on BIO's 2020 Initiatives on Behalf of the Industry given by Jeremy Levin, CEO of Ovid Therapeutics Chair of the Board of Directors of BIO. The industry was established in 1970’s during an era of bipartisan…

Jennifer Bright with the Innovation and Value Initiative recently wrote for Morning Consult that the U.S. is “engaged in the challenging but important conversation about how to assess the value of pharmaceuticals.”  It’s a conversation that should be transparent and open to everyone,…

The 340B Drug Discount Program is in the spotlight with the release of a new report from the Government Accountability Office (GAO) calling attention to oversight of the program designed to help vulnerable patients gain access to affordable prescription drugs. As the findings show, the program,…

This week, Congress is expected to consider a USMCA trade agreement that does NOT include stronger IP protections for American innovators who develop biologic medicines. While the removal of these provisions is being hailed as a defeat for Big Pharma, here are three key points to keep in mind as…

In a story entitled, “CMS Blames Medicare Part B Hikes on Drug Costs,” writers for Politico Pulse note: “The agency [Centers for Medicare & Medicaid Services] on Friday announced a $9 monthly premium increase and $13 annual deductible hike, but argued that the White House is working to bring…